ProCE Banner Activity

New Options for Patients With Relapsed/Refractory ALL

Clinical Thought
The use of novel targeted therapies and immunotherapies is showing promise in ALL. These agents are achieving great responses not only in pediatric patients but also in adult patients with relapsed/refractory ALL.

Released: February 20, 2015

Expiration: February 19, 2016

No longer available for credit.

Share

Faculty

Elias Jabbour

Elias Jabbour, MD

Assistant Professor
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Novartis Oncology

Faculty Disclosure

Primary Author

Elias Jabbour, MD

Assistant Professor
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Elias Jabbour, MD, has disclosed that he has received consulting fees from Ariad, Bristol-Myers Squibb, Pfizer, and Teva.